创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

长链非编码RNA在肾癌进展中的作用及临床应用前景

The Role of Long Non-coding RNAs in the Development of Renal Cancer and Prospect of Clinical Application

  • 摘要: 肾癌是最常见的泌尿系统肿瘤之一,其中有85%属于透明肾细胞癌。肾癌患者每年新增约30万例,转移性患者的5年生存率仅为10%,因此发现肾癌相关生物标志物及治疗靶标是提高肾癌临床治疗效果的必然要求。长链非编码RNA(lncRNAs)是指长度大于200个核苷酸且缺乏蛋白编码能力的RNA分子。大量文献报道lncRNAs在肾癌的发生发展过程中发挥重要的调控作用,其可作为促癌基因或抑癌基因通过多种信号通路调控肾癌细胞的增殖、迁移、侵袭、凋亡等过程。综述近年lncRNAs在肾癌中的研究进展,为lncRNAs对于肾癌的诊断、预后或靶向治疗提供理论依据。

     

    Abstract: Renal cell carcinoma (RCC) is one of the most common urinary system tumors.85% of RCC belong to clear cell renal cell carcinoma (ccRCC), with the estimated incidence of about 300, 000 new cases each year and a 5-year survival rate of metastatic patients of 10%.Thus, the discovery of RCC diagnostic biomarkers and therapeutic targets is an inevitable requirement to improve the effectiveness of RCC treatment.Long non-coding RNAs (lncRNAs), which are RNA molecules larger than 200 nucleotides in length with lack of proteincoding ability, have been widely reported in the regulation of the development of RCC.They may function as an oncogene or a tumor suppressor gene to regulate the proliferation, migration, invasion, and apoptosis of renal cancer cells via multiple signaling pathways.This review summarizes the recent studies of lncRNAs in renal cancer, in an attempt to provide a theoretical basis for the diagnosis, prognosis or therapeutic targets of renal cancer.

     

/

返回文章
返回